TNFRSF17 and congenital rubella syndrome: In multiple myeloma, investigations targeting the B-cell maturation antigen (BCMA) yielded encouraging outcomes with reversible toxic effects such as cytokine release syndrome (CRS) and pancytopenia13–17.